GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings

Initial findings showed significant improvements from baseline in the disease-specific, patient-reported quality of life scores in both the high and low dose AAV-GAD groups, with no significant change in the sham group at 26 weeks.:

Source: Neurology Read More